Loxo Oncology, Inc. (LOXO) VP Jennifer Burstein Sells 1,700 Shares
Loxo Oncology, Inc. (NASDAQ:LOXO) VP Jennifer Burstein sold 1,700 shares of Loxo Oncology stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $73.73, for a total transaction of $125,341.00. Following the completion of the sale, the vice president now owns 1,700 shares of the company’s stock, valued at $125,341. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Loxo Oncology, Inc. (NASDAQ:LOXO) traded up 0.91% on Wednesday, reaching $74.19. 381,596 shares of the company were exchanged. Loxo Oncology, Inc. has a 12-month low of $17.14 and a 12-month high of $83.12. The stock’s market capitalization is $2.21 billion. The firm has a 50 day moving average price of $74.65 and a 200-day moving average price of $55.69.
Loxo Oncology (NASDAQ:LOXO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.99) by $0.15. During the same period last year, the firm posted ($0.77) EPS. On average, analysts predict that Loxo Oncology, Inc. will post ($4.34) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.watchlistnews.com/loxo-oncology-inc-loxo-vp-jennifer-burstein-sells-1700-shares/1496645.html.
A number of hedge funds have recently bought and sold shares of LOXO. Ameritas Investment Partners Inc. boosted its stake in Loxo Oncology by 31.3% in the second quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 419 shares in the last quarter. Legal & General Group Plc boosted its stake in Loxo Oncology by 8.4% in the first quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 284 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in Loxo Oncology by 4,388.0% in the second quarter. BNP Paribas Arbitrage SA now owns 2,244 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 2,194 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Loxo Oncology during the second quarter valued at about $228,000. Finally, Marshall Wace LLP purchased a new stake in Loxo Oncology during the second quarter valued at about $233,000.
A number of equities research analysts have recently weighed in on the stock. Stifel Nicolaus reiterated a “buy” rating and issued a $94.00 price target (up from $71.00) on shares of Loxo Oncology in a research report on Thursday, August 10th. BidaskClub downgraded shares of Loxo Oncology from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. Zacks Investment Research downgraded shares of Loxo Oncology from a “buy” rating to a “hold” rating in a research report on Saturday. Ifs Securities reiterated an “outperform” rating on shares of Loxo Oncology in a research report on Tuesday, August 8th. Finally, BTIG Research reiterated a “buy” rating and issued a $75.00 price target on shares of Loxo Oncology in a research report on Thursday, August 3rd. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Loxo Oncology currently has a consensus rating of “Buy” and a consensus price target of $79.67.
Loxo Oncology Company Profile
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.